Scholarlink

Objective <p>To describe seven cases of patulous Eustachian tube (PET, “Tuba aperta”) arising in adult patients undergoing significant weight loss with GLP-1 receptor agonists (semaglutide [Ozempic<sup>®</sup>] or tirzepatide [Mounjaro<sup>®</sup>]).</p> Methods <p>Retrospective descriptive case series of patients presenting to our otolaryngology clinic between June 2024 and June 2025 with symptoms of autophony, aural fullness, and audible breathing. All had initiated GLP-1 agonist therapy ≥ 3 months prior and achieved ≥ 8% body-weight reduction. Diagnosis of PET was confirmed by patient symptoms, otoscopy, digital volume tomography, reflex decay tympanometry and tubomanometry.</p> Results <p>Seven patients (5 female, 2 male; age 28–56 years) developed bilateral (<i>n</i> = 5) or unilateral (<i>n</i> = 2) PET after 4–10 months of GLP-1 therapy. Weight loss ranged from 8.2 to 18.7% of baseline. Common symptoms were autophony (7/7), intermittent aural fullness (6/7), and hearing one’s own breathing (5/7). Conservative management led to symptom improvement in one patient; six required injections of VOX-Implants<sup>®</sup> into the affected Eustachian tubes with resolution of symptoms.</p> Conclusion <p>Significant weight loss from GLP-1 receptor agonists may predispose susceptible individuals to PET. Clinicians should be aware of this potential otologic side effect and consider early conservative measures.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss

  • 期刊论文

  • 发表日期：

    2025年7月28日

查看全文
  • Holger Sudhoff

摘要

Objective

To describe seven cases of patulous Eustachian tube (PET, “Tuba aperta”) arising in adult patients undergoing significant weight loss with GLP-1 receptor agonists (semaglutide [Ozempic®] or tirzepatide [Mounjaro®]).

Methods

Retrospective descriptive case series of patients presenting to our otolaryngology clinic between June 2024 and June 2025 with symptoms of autophony, aural fullness, and audible breathing. All had initiated GLP-1 agonist therapy ≥ 3 months prior and achieved ≥ 8% body-weight reduction. Diagnosis of PET was confirmed by patient symptoms, otoscopy, digital volume tomography, reflex decay tympanometry and tubomanometry.

Results

Seven patients (5 female, 2 male; age 28–56 years) developed bilateral (n = 5) or unilateral (n = 2) PET after 4–10 months of GLP-1 therapy. Weight loss ranged from 8.2 to 18.7% of baseline. Common symptoms were autophony (7/7), intermittent aural fullness (6/7), and hearing one’s own breathing (5/7). Conservative management led to symptom improvement in one patient; six required injections of VOX-Implants® into the affected Eustachian tubes with resolution of symptoms.

Conclusion

Significant weight loss from GLP-1 receptor agonists may predispose susceptible individuals to PET. Clinicians should be aware of this potential otologic side effect and consider early conservative measures.